Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | lutetium Lu 177 dotatate |
Synonyms | |
Therapy Description |
Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog which may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
lutetium Lu 177 dotatate | Lutathera | LuTate|177Lu-Octreotate|177 Lu-DOTA-Tyr3-octreotate | Lutathera (lutetium Lu 177 dotatate) is a radiolabeled somatostatin analog which may selectively kill somatostatin receptor-positive tumor cells (PMID: 28076709). Lutathera (lutetium Lu 177 dotatate) is FDA approved for use in patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04609592 | Phase I | lutetium Lu 177 dotatate | Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery | Recruiting | USA | 0 |
NCT02754297 | Phase II | lutetium Lu 177 dotatate | Personalized PRRT of Neuroendocrine Tumors (P-PRRT) | Recruiting | CAN | 0 |
NCT04082520 | Phase II | lutetium Lu 177 dotatate | Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy | Recruiting | USA | 0 |
NCT04529044 | Phase II | lutetium Lu 177 dotatate | 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer | Not yet recruiting | USA | 0 |
NCT03971461 | Phase II | lutetium Lu 177 dotatate | Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma | Recruiting | USA | 0 |
NCT04106843 | Phase II | lutetium Lu 177 dotatate | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Withdrawn | USA | 0 |
NCT04954820 | Phase II | lutetium Lu 177 dotatate | Assessment of the Schema of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor (ReLUTH) | Recruiting | FRA | 0 |
NCT04665739 | Phase II | Everolimus lutetium Lu 177 dotatate | Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Suspended | USA | 0 |
NCT04614766 | Phase Ib/II | 131I-MIBG + lutetium Lu 177 dotatate lutetium Lu 177 dotatate | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3) | Not yet recruiting | USA | 0 |
NCT02230176 | Phase II | Sunitinib lutetium Lu 177 dotatate | Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II (OCCLURANDOM) | Recruiting | FRA | 0 |